Humacyte’s (HUMA) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Humacyte (NASDAQ:HUMA) in a report published on Monday morning,Benzinga reports. D. Boral Capital currently has a $25.00 price objective on the stock.

Several other analysts have also commented on the stock. BTIG Research lowered their price target on shares of Humacyte from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday, October 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a report on Wednesday, October 8th. TD Cowen cut their price target on Humacyte from $5.00 to $3.50 and set a “buy” rating for the company in a report on Tuesday, August 12th. Wall Street Zen downgraded Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday, August 17th. Finally, UBS Group set a $6.00 price objective on Humacyte in a research note on Monday, October 13th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.71.

Humacyte Price Performance

Humacyte stock opened at $1.25 on Monday. The firm has a market capitalization of $197.96 million, a PE ratio of -2.78 and a beta of 1.88. Humacyte has a 52 week low of $1.15 and a 52 week high of $6.77. The firm’s 50-day simple moving average is $1.64 and its 200 day simple moving average is $1.95. The company has a quick ratio of 1.93, a current ratio of 2.45 and a debt-to-equity ratio of 2.97.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Monday, August 11th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.09). The business had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.94 million. On average, equities research analysts predict that Humacyte will post -1.27 EPS for the current fiscal year.

Insider Buying and Selling at Humacyte

In other news, CEO Laura E. Niklason sold 591,685 shares of Humacyte stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total value of $934,862.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Brady W. Dougan sold 591,685 shares of the company’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total value of $934,862.30. The disclosure for this sale is available in the SEC filing. Insiders have sold 4,482,090 shares of company stock worth $7,466,382 in the last 90 days. Insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Lazari Capital Management Inc. acquired a new stake in shares of Humacyte in the second quarter worth approximately $27,000. Prudential Financial Inc. purchased a new position in Humacyte during the second quarter worth approximately $28,000. Financial Advisors Network Inc. acquired a new position in shares of Humacyte in the 2nd quarter valued at $28,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Humacyte during the 2nd quarter valued at $30,000. Finally, Valeo Financial Advisors LLC purchased a new stake in shares of Humacyte during the 2nd quarter valued at $32,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.